

Bijlage bij Kamervragen over medicinale cannabis

Literatuurlijst (1-84) uit:

Hazekamp A, Grotenhermen F. Review on clinical studies with cannabis and cannabinoids 2005-2009. Cannabinoids 2010;5 (special issue):1-21

1. Abrams DI, Hilton JF, Leiser RJ, Shade SB, Elbeik TA, Aweeka FT, Benowitz NL, Bredt BM, Kosel B, Aberg JA, Deeks SG, Mitchell TF, Mulligan K, Bacchetti P, McCune JM, Schambelan M. Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. *Ann. Intern. Med.* 2003;139(4):258-266.
2. Abrams DI, Jay CA, Shade SB, Vizoso H, Reda H, Press S, Kelly ME, Rowbotham MC, Petersen KL. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. *Neurology* 2007;68(7):515-521.
3. Agurell S, Carlsson S, Lindgren JE, Ohlsson A, Gillespie H, Hollister L. Interactions of delta 1- tetrahydrocannabinol with cannabiniol and cannabidiol following oral administration in man. Assay of cannabiniol and cannabidiol by mass fragmentography. *Experientia* 1981;37(10):1090-1092.
4. Aragona M, Onesti E, Tomassini V, Conte A, Gupta S, Gilio F, Pantano P, Pozzilli C, Inghilleri M. Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study. *Clin. neuropharmacol.* 2009;32(1):41-47.
5. Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M, LaMoreaux L, Garofalo E. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. *JAMA* 1998;280:1831-1836.
6. Bateman DN. Delta-9-tetrahydrocannabinol and gastric emptying. *Br. J. Clin. Pharmacol.* 1983; 15:749-751.
7. Beal J, Flynn N. AIDS-associated anorexia. *J. Physicians Assoc. AIDS Care* 1995;2(1):19-22.
8. Beaulieu P. Effects of nabilone, a synthetic cannabinoid, on postoperative pain. *Can. J. Anaesth.* 2006;53(8):769-775.
9. Ben Amar M. Cannabinoids in medicine: A review of their therapeutic potential. *J. Ethnopharm.* 2006;105:1-25.
10. Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde SDE, Brandi I, Moriello AS, Davis JB, Mechoulam R, Di Marzo V. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. *Br. J. Pharmacol.* 2001;134(4):845-52.
11. Blake DR, Robson P, Ho M, Jubbs RW, McCabe CS. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. *Rheumatology (Oxford)* 2006;45(1):50-52.
12. Bornheim LM, and Grillo MP. Characterization of cytochrome P450 3A inactivation by cannabidiol: possible involvement of cannabidiolhydroxyquinone as a P450 inactivator. *Chem. Res. Toxicol.* 1998;11(10):1209-1216.
13. Bornheim LM, Kim KY, Li J, Perotti BY, Benet LZ. Effect of cannabidiol pretreatment on the kinetics of tetrahydrocannabinol metabolites in mouse brain. *Drug Metab. Dispos.* 1995;23(8): 825-831.
14. Brady CM, DasGupta R, Wiseman OJ, Dalton CM, Berkley KJ, Fowler CJ. The effect of cannabis based medicinal extract on lower urinary tract dysfunction in advanced multiple sclerosis: preliminary results. *Journal of Neurology, Neurosurgery and Psychiatry* 2002;72:139
15. Christie MJ, Mallet C. Endocannabinoids can open the pain gate. *Sci. Signal.* 2009;2(88):pe57.
16. Collin C, Davies P, Mutiboko IK, Ratcliffe S; Sativex Spasticity in MS Study Group. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. *Eur. J. Neurol.* 2007;14(3):290-296.

17. Conte, A, Marini Bettolo C, Onesti E, Frasca V, Iacovelli E, Gilio F, Giacomelli E, Gabriele M, Aragona M, Tomassini V, Pantano P, Pozzilli C, Inghilleri M. Cannabinoid-induced effects on the nociceptive system: A neurophysiological study in patients with secondary progressive multiple sclerosis. *European Journal of Pain* 2009;13:472-477.
18. Corchero J, Manzanares J, Fuentes JA. Cannabinoid/opioid crosstalk in the central nervous system. *Crit. Rev. Neurobiol.* 2004;16:159-172.
19. Costa B, Trovato AE, Comelli F, Giagnoni G, Colleoni M. The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. *Eur. J. Pharmacol.* 2007;556(1-3):75-83.
20. Coyne KS, Matza LS, Thompson CL. The responsiveness of the Overactive Bladder Questionnaire (OAB-q). *Qual. Life Res.* 2005;14:849-855.
21. Craft RM. Sex differences in behavioral effects of cannabinoids. *Life Sci.* 2005;77:2471-2478.
22. D'Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, Gueorguieva R, Cooper TB, Krystal JH. Delta-9-tetrahydro-cannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. *Biol. Psychiatry* 2005;57(6):594-608.
23. Ellis RJ, Toperoff W, Vaida F, van den Brande G, Gonzales J, Gouaux B, Bentley H, Atkinson JH. Smoked Medicinal Cannabis for Neuropathic Pain in HIV: A Randomized, Crossover Clinical Trial. *Neuropsychopharmacology* 2009;34(3): 672-680.
24. Esfandyari T, Camilleri M, Busciglio I, Burton D, Baxter K, Zinsmeister AR. Effects of a cannabinoid receptor agonist on colonic motor and sensory functions in humans: a randomized, placebocontrolled study. *Am. J. Physiol. Gastrointest. Liver Physiol.* 2007;293(1):G137-G145.
25. Esfandyari T, Camilleri M, Ferber I, Burton D, Baxter K, Zinsmeister AR. Effect of a cannabinoid agonist on gastrointestinal transit and postprandial satiation in healthy human subjects: a randomized, placebo-controlled study. *Neurogastroenterol. Motil.* 2006;18(9):831-838.
26. Farrar JT, Young JP, La Moreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. *Pain* 2000;94:149-158.
27. Frank B, Serpell MG, Hughes J, Matthews JN, Kapur D. Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. *BMJ* 2008;336(7637):199-201.
28. Freeman RM, Adekanmi O, Waterfield MR, Waterfield AE, Wright D, Zajicek J. The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS). *Int. Urogynecol. J. Pelvic Floor Dysfunct.* 2006;17(6):636-641.
29. Giuffrida A, Leweke FM, Gerth CW, Schreiber D, Koethe D, Faulhaber J, Klosterkötter J, Piomelli D. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. *Neuropsychopharmacology* 2004;29(11):2108-2114.
30. Goldstein I, Siroky MB, Sax DS, Krane RJ. Neurourologic abnormalities in multiple-sclerosis. *J. Urol.* 1982;128(3):541-545.
31. Guy GW, Robson P. A phase 1, double blind, three way crossover study to assess the pharmacokinetic profile of cannabis based medicinal extract (CBME) administered sublingually in variant cannabinoid ratios in normal healthy male volunteers. *J. Cannabis Ther.* 2003;3:121-152.
32. Guzmán M, Duarte MJ, Blázquez C, Ravina J, Rosa MC, Galve-Roperh I, Sánchez C, Velasco G, González-Feria L. A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. *Br. J. Cancer* 2006;95(2):197-203.
33. Guzmán M. Cannabinoids: potential anticancer agents. *Nat. Rev. Cancer* 2003;3:745-755.
34. Haney M, Gunderson EW, Rabkin J, Hart CL, Vosburg SK, Comer SD, Foltin RW. Dronabinol and marijuana in HIV-positive marijuana smokers. Caloric intake, mood, and sleep. *J. Acquir. Immune Defic. Syndr.* 2007;45(5):545-554.

35. Haney M, Rabkin J, Gunderson E, Foltin RW. Dronabinol and marijuana in HIV(+) marijuana smokers: acute effects on caloric intake and mood. *Psychopharmacology (Berl)* 2005;181(1): 170-178.
36. Hepler RS, Frank IR. Marijuana smoking and intraocular pressure. *JAMA* 1971;217(10):1392.
37. Holdcroft A, Maze M, Doré C, Tebbs S, Thompson S. A multicenter dose-escalation study of the analgesic and adverse effects of an oral cannabis extract (Cannador) for postoperative pain management. *Anesthesiology* 2006;104(5):1040-1046.
38. Hunt CA, Jones RT, Herning RI, Bachman J. Evidence that cannabidiol does not significantly alter the pharmacokinetics of tetrahydrocannabinol in man. *J. Pharmacokinet. Biopharm.* 1981; 9(3):245-260.
39. Institute of Medicine, Marijuana and medicine: assessing the scientific base. National Academy Press, Washington DC, MD. 1999.
40. Iversen L. Cannabis and the brain. *Brain* 2003;126:1252-1270.
41. Jaeger W, Benet LZ, Bornheim LM. Inhibition of cyclosporine and tetrahydrocannabinol metabolism by cannabidiol in mouse and human microsomes. *Xenobiotica* 1996;26(3):275-284.
42. Jager G, Kahn RS, Van Den Brink W, Van Ree JM, Ramsey NF. Long-term effects of frequent cannabis use on working memory and attention: an fMRI study. *Psychopharmacol (Berl)* 2006;185:358-368.
43. Jay WM, Green K. Multiple drop study of topically applied 1% delta-9-tetrahydrocannabinol in human eyes. *Arch Ophthalmol.* 1983;101:591-593.
44. Katona S, Kaminski E, Sanders H, Zajicek J. Cannabinoid influence on cytokine profile in multiple sclerosis. *Clin. Exp. Immunol.* 2005; 140(3):580-585.
45. Kavia R, De Ridder D, Sarantis N, Constantinescu C, Fowler. Randomised controlled trial of cannabis based medicine (CBM, Sativex®) to treat detrusor overactivity in multiple sclerosis. *Neurourology and Urodynamics* 2006;25:166-166.
46. Kraft B, Frickey NA, Kaufmann RM, Reif M, Frey R, Gustorff B, Kress HG. Lack of analgesia by oral standardized cannabis extract on acute inflammatory pain and hyperalgesia in volunteers. *Anesthesiology* 2008;109(1):101-110.
47. Leweke FM, Koethe D, Gerth CW, Nolden BM, Schreiber D, Hänsel A, Neatby MA, Juelicher A, Hellmich M, Klosterkötter J. Cannabidiol as an antipsychotic. A double-blind, controlled clinical trial on cannabidiol vs. amisulpride in acute schizophrenia. Abstract for oral sessions / *European Psychiatry* 2007;22:S14.02.
48. Lynch MA, Clark AJ. Cannabis reduces opioid dose in the treatment of chronic non-cancer pain. *Journal of Pain and Symptom Management* 2003;25:496-498.
49. Maldonado R, Valverde O. Participation of the opioid system in cannabinoid-induced antiception and emotional-like responses. *European Neuropsychopharmacology* 2003;13:401-410.
50. Manara L, Croci T, Guagnini F, Rinaldi-Carmona M, Maffrand JP, Le Fur G, Mukenge S, Ferla G. Functional assessment of neuronal cannabinoid receptors in the muscular layers of human ileum and colon. *Dig. Liver Dis.* 2002;34:262-269.
51. Mechoulam R, Hanus L. Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects. *Chem. Phys. Lipids* 2002;121(1-2):35-43.
52. Meiri E, Jhangiani H, Vredenburg JJ, Barbato LM, Carter FJ, Yang HM, Baranowski V. Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. *Curr. Med. Res. Opin.* 2007;23(3):533-543.
53. Millan MJ. Descending control of pain. *Prog. Neurobiol.* 2002;66:355-474.
54. Narang S, Gibson D, Wasan AD, Ross EL, Michna E, Nedeljkovic SS, Jamison RN. Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy. *J. Pain* 2008;9(3):254-264
55. Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D. Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. *Pain* 2007;133(1-3):210-220.
56. Petitet F, Jeantaud B, Reibaud M, Imperato A, Dubroeuq MC. Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of Δ9-

- tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. *Life Sci.* 1998;63(1):PL1-6.
57. Pingsger M, Schimetta W, Volc D, Hiermann E, Riederer F, Pölz W. [Benefits of an add-on treatment with the synthetic cannabinomimetic nabilone on patients with chronic pain--a randomized controlled trial] [Article in German]. *Wien Klin. Wochenschr.* 2006;118(11-12):327-335.
 58. Plange N, Arend KO, Kaup M, Doehmen B, Adams H, Hendricks S, Cordes A, Huth J, Sponsel WE, Remky A. Dronabinol and retinal hemodynamics in humans. *Am. J. Ophthalmol.* 2007;143(1):173-174.
 59. Redmond WJ, Goffaux P, Potvin S, Marchand S. Analgesic and antihyperalgesic effects of nabilone on experimental heat pain. *Curr. Med. Res. Opin.* 2008;24(4):1017-1024.
 60. Roberts JD, Gennings C, Shih M. Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and morphine. *Eur. J. Pharmacol.* 2006;530(1-2):54-58.
 61. Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. *Neurology* 2005;65(6):812-819.
 62. Rog DJ, Nurmikko TJ, Young CA. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. *Clin. Ther.* 2007;29(9):2068-2079.
 63. Russo E, Guy GW. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. 2006; *Med. Hypotheses* 66(2):234-46.
 64. Sandrini G, Arrigo A, Bono G, Nappi G. The nociceptive flexion reflex as a tool for exploring pain control systems in headache and other pain syndromes. *Cephalalgia* 1993;13:21-27.
 65. Seeling W, Kneer L, Büchele B, Gschwend JE, Maier L, Nett C, Simmet T, Steffen P, Schneider M, Rockemann M. [Delta(9)-tetrahydrocannabinol and the opioid receptor agonist piritramide do not act synergistically in postoperative pain] [Article in German]. *Anaesthesist.* 2006;55(4):391-400.
 66. Shakespeare DT, Boggild M, Young C. Antispasticity agents for multiple sclerosis (Cochrane Review). In: *The Cochrane Library, Issue 3.* Oxford: Update Software: 2003.
 67. Siegling A, Hofmann HA, Denzer D, Mauler F, De Vry J. Cannabinoid CB(1) receptor upregulation in a rat model of chronic neuropathic pain. *Eur. J. Pharmacol.* 2001;415(1):R5-7.
 68. Skrabek RQ, Galimova L, Ethans K, Perry D. Nabilone for the treatment of pain in fibromyalgia. *J. Pain* 2008;9(2):164-173.
 69. Smith FL, Cichewicz D, Martin ZL, Welch SP. The enhancement of morphine antinociception in mice by delta9-tetrahydrocannabinol. *Pharmacol. Biochem. Behav.* 1998;60:559-566.
 70. Strasser F, Luftner D, Possinger K, Ernst G, Ruhstaller T, Meissner W, Ko YD, Schnelle M, Reif M, Cerny T. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. *J. Clin. Oncol.* 2006;24(21):3394-3400.
 71. Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. *BMJ* 2004;329(7460):253.
 72. Sylvestre DL, Clements BJ, Malibu Y. Cannabis use improves retention and virological outcomes in patients treated for hepatitis C. *Eur. J. Gastroenterol. Hepatol.* 2006;18(10):1057-1063.
 73. Tomida I, Azuara-Blanco A, House H, Flint M, Pertwee RG, Robson PJ. Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study. *J. Glaucoma* 2006;15(5):349-353.
 74. Tseng AH, Harding JW, Craft RM. Pharmacokinetic factors in sex differences in Delta 9-tetrahydrocannabinol-induced behavioral effects in rats. *Behav. Brain Res.* 2004;154:77-83.

75. Verdejo-Garcia A, Lopez-Torrecillas F, Gimenez CO, Pérez-García M. Clinical implications and methodological challenges in the study of the neuropsychological correlates of cannabis, stimulant, and opioid abuse. *Neuropsychol. Rev.* 2004;14:1-41.
76. Wade DT, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. *Mult. Scler.* 2004;10(4):434-441.
77. Wade DT, Makela PM, House H, Bateman C, Robson P. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. *Mult. Scler.* 2006;12(5):639-645.
78. Wallace M, Schulteis G, Atkinson JH, Wolfson T, Lazzaretto D, Bentley H, Gouaux B, Abramson I. Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers. *Anesthesiology* 2007;107(5): 785-796.
79. Ware MA, Ducruet T, Robinson AR. Evaluation of herbal cannabis characteristics by medical users: a randomized trial. *Harm Reduct. J.* 2006; 3:32.
80. Wilsey B, Marcotte T, Tsodikov A, Millman J, Bentley H, Gouaux B, Fishman S. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. *J. Pain* 2008; 9(6):506-521.
81. Wissel J, Haydn T, Müller J, Brenneis C, Berger T, Poewe W, Schelosky LD. Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain: a doubleblind placebo-controlled cross-over trial. *J. Neurol.* 2006;253(10):1337-1341.
82. Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A; UK MS Research Group. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebocontrolled trial. *Lancet* 2003;362(9395):1517-1526.
83. Zajicek JP, Sanders HP, Wright DE, Vickery PJ, Ingram WM, Reilly SM, Nunn AJ, Teare LJ, Fox PJ, Thompson AJ. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. *J. Neurol. Neurosurg. Psychiatry* 2005;76(12):1664-1669.
84. Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG. Action of cannabidiol on the anxiety and other effects produced by delta-9-THC in normal subjects. *Psychopharmacology* 1982;76:245-250.

Aanvullende publicaties:

85. Ben Amar M. Cannabinoids in medicine: A review of their therapeutic potential. *J. Ethnopharm.* 2006;105:1-25.
86. Kogan NM, Mechoulam R. Cannabinoids in health and disease. *Dialogues in Clinical Neuroscience* 2007;9 (no.4)
87. Grotenhermen F. Cannabinoids. *Current Drug Targets – CNS & Neurological Disorders*, 2005, 4, 507-530.
88. Mechoulam R, Peters M, Murillo-Rodriguez E, Hanus LO. Cannabidiol – Recent advances. *Chemistry & Biodiversity* 2007: Vol. 4
89. Elikottil J, Gupta P, Gupta K. The analgesic potential of cannabinoids. *Journal of Opioid Management* 2009: 5:6